![NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.](/Media/Default/NewsItem/NewsArticleImage/antibiotic%20resistance%20lab%20culture%20--%20original.jpg)
NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.